Title: Preclinical diagnosis of diabetic polyneuropathy: the role of neurospecific proteins

Katsiaryna Serabrova

Gomel State Medical University, Belarus


Katsiaryna Serabrova graduated from Gomel State Medical University in 2009. Since 2012 to present  she has been working in position of neurologist in neurology unit in Gomel Regional Hospital of veterans and in position of  Assistant in department of  Neurology and neurosurgery in  Gomel State Medical University. In recent years she studied several qualification courses and participate in many republican and international conferences. Her scientific interests are stroke, sleep disorders, CPAP-therapy, diabetic polyneuropathy.


The aim of study was to estimate the role of neurospecific proteins in  preclinical diagnosis of DPNP.

 Methods. In 2012-2017  there were examined 181 patients (men - 118, women - 63, average age 38.00 ± 20.18 years). We estimated the neurological examination and conducted electromyography (EMG).

All patients were divided into 2 groups. The group №1 consisted of 81 patients with a confirmed diagnosis of DM and preclinical DPNP. 100 patients without endocrine pathology and EMG changes were included in the group №2. The level of neurospecific proteins (neuronspecific enolase (NSE) and protein S 100) was determined in the blood of all patients.


In 59% of patients of the group №1 (n = 48) the level of NSE was from 0.17 to 2 ng / ml.

The incidence of higher NSE level in patients of the group №1 decreased from 18.5% (n = 15) for values from 2.07 to 4.2 ng / ml, 14% (n = 11) for values from 4.25 to 5 , 94 ng / ml, up to 6% (n = 5) for values from 6.15 to 6.93 ng / ml. The NSE level exceeding 12.0 ng / ml was detected in 2.5% of cases (n = 2).

The majority of patients of the group №2 (n = 55; 55%) had a NSE level from 8.01 to 12.0 ng / ml.

In patients of the group №2 the NSE level more than 12.0 ng / ml was found more often (n = 16; 16%) than  in patients of the group №1.

The level of S 100 protein did not differ in patients of both groups.

Conclusion. NCE is a sensitive early marker of the preclinical DPNP. The NSE level in patients is mostly in the range from 0.17 to 2 ng / ml and less often in the range from 2.07 to 6.93 ng / ml.

The results of the study can be used

-by practitioners for the timely diagnosis of diabetic polyneuropathy

-in further scientific studies on DPNP